Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has terminated its previously announced plan to subscribe for a BOC Structured Deposit II wealth management product with a principal amount of RMB980 million, exercising its right to withdraw within the investment cooling-off period, which means no funds were paid and no fees or penalties will be incurred. The company attributed the cancellation to an adjustment of its wealth management strategies and stated that the decision is not expected to have any material adverse impact on the group’s existing business, operations or financial condition, suggesting that its core activities and financial stability remain intact despite the change in investment plans.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company based in the People’s Republic of China. It operates in the biotechnology and pharmaceutical industry, focusing on the research, development and commercialization of biopharmaceutical products for healthcare markets.
Average Trading Volume: 629,683
Technical Sentiment Signal: Buy
Current Market Cap: HK$100.7B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.